Early Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI Therapy

Recruiting

EGFR, ALK, ROS1, BRAF TKIEarly Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI Therapy

Sponsor:

University of Colorado, Denver

Code:

NCT03042221

Conditions

Non-Small Cell Carcinoma of Lung, TNM Stage 4

Non-Small Cell Lung Cancer

EGFR Gene Mutation

ALK Gene Mutation

ROSE Cluster 1

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-02-13. This information was provided to ClinicalTrials.gov by University of Colorado, Denver on 2025-02-06.